Top Story

EoE patients improve with atopic dermatitis drug Dupixent

EoE patients improve with atopic dermatitis drug Dupixent
October 17, 2017

ORLANDO — Dupixent, a fully human monoclonal antibody approved for the treatment of atopic dermatitis, improved symptoms and objective measures of disease in patients with eosinophilic esophagitis, according to late-breaking research presented at the World Congress of Gastroenterology at ACG 2017.

Dupixent (dupilumab, Sanofi/Regeneron) “significantly improved dysphagia, esophageal eosinophil counts, endoscopic features, histology and esophageal distensibility in adults with active EoE compared with placebo,” Evan S. Dellon, MD, associate professor of medicine and epidemiology at the Center for Esophageal Diseases and Swallowing, University of North Carolina School of Medicine, Chapel Hill, said during his presentation.

Meeting News

Endoscopic therapy effective in Barrett’s carcinoma, dysplasia

October 16, 2017
ORLANDO — Endoscopic therapy was equally effective in patients with Barrett’s esophagus who had intramucosal carcinoma or high-grade dysplasia, according to…
In the Journals

Breastfeeding lowers, NICU raises risk of EoE in genetically susceptible kids

October 11, 2017
Environmental exposures in early life, including breastfeeding and NICU admission, appeared to impact the risk for developing eosinophilic esophagitis by interacting…
In the Journals

Intervention reduces unnecessary PPI use in patients with upper GI bleeding

October 9, 2017
A trainee-led intervention reduced unnecessary proton pump inhibitor infusions in patients hospitalized with upper GI bleeding, according to a research letter published…
More Headlines »